Attention deficit hyperactivity disorder controversies

October is ADHD Awareness Month

Retrieved on: 
Wednesday, October 25, 2023
JAMA, FDA, Drug Enforcement Administration, Attention, Education, Food, Child, Policy, American Medical Association, National Disability Employment Awareness Month, Prevalence, US Food Sovereignty Alliance, DEA, Conference, Journal, Drug, Approximation error, Letter, White, Caregiver, COVID-19, Annual International Conference on Real Options, ADDA, Woman, Patient, Diagnosis, Attention deficit hyperactivity disorder controversies, ADHD, ACO, Parent, Mental health, Dietary supplement, Nursing

Each October during ADHD Awareness Month, CHADD joins forces with the ADHD Coaches Organization (ACO) and the Attention Deficit Disorder Association (ADDA) to build a stronger understanding of ADHD, and to provide valuable programming and resources.

Key Points: 
  • Each October during ADHD Awareness Month, CHADD joins forces with the ADHD Coaches Organization (ACO) and the Attention Deficit Disorder Association (ADDA) to build a stronger understanding of ADHD, and to provide valuable programming and resources.
  • The theme for Awareness Month this year is Moving Forward with ADHD in 2023.
  • This ADHD Awareness Month, the experts at CHADD have identified three pressing concerns in need of attention if we are to move forward as a community in enabling individuals with ADHD to lead successful lives.
  • Beyond ADHD Awareness Month, the coalition members―CHADD, ACO and ADDA―will host the 2023 Annual International Conference on ADHD in Baltimore, Maryland, from November 30 to December 2, followed by an online conference option on December 5 and 6.

Corium Launches Innovative ADHD Treatment AZSTARYS™ (serdexmethylphenidate and dexmethylphenidate) in the U.S. for Patients Age 6 Years and Older

Retrieved on: 
Wednesday, July 21, 2021
Psychoactive drugs, Stimulants, Methylphenidate, Amphetamine, Nootropics, Norepinephrine-dopamine reuptake inhibitors, Attention deficit hyperactivity disorder, Pemoline, Dexmethylphenidate, Attention deficit, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

Corium, a wholly-owned portfolio company of Gurnet Point Capital (GPC), will lead the U.S. commercialization of AZSTARYS.

Key Points: 
  • Corium, a wholly-owned portfolio company of Gurnet Point Capital (GPC), will lead the U.S. commercialization of AZSTARYS.
  • Corium will offer programs to support patients, providers, and health systems through CoriumCaresTM.
  • AZSTARYS is a central nervous system (CNS) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged 6 years and older.
  • Do not take AZSTARYS if you or your child are:
    allergic to serdexmethylphenidate, methylphenidate, or any of the ingredients in AZSTARYS.

Drug Relieves Persistent Daydreaming, Fatigue, and Brain Sluggishness in Adults with ADHD

Retrieved on: 
Tuesday, June 29, 2021
Attention deficit hyperactivity disorder, Psychiatry, Childhood psychiatric disorders, Branches of biology, Abnormal psychology, Educational psychology, Amphetamine, Methylphenidate, Sluggish cognitive tempo, Adult attention deficit hyperactivity disorder, Stimulant, Attention deficit hyperactivity disorder controversies

Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.

Key Points: 
  • Adler, who directs the adult ADHD program at NYU Langone Health, says until now stimulants have only been shown to improve sluggish cognitive tempo symptoms in children with ADHD.
  • The NYU Langone-Mount Sinai team's findings, he adds, are the first to show that such treatments also work in adults.
  • "These findings highlight the importance of assessing symptoms of sluggish cognitive tempo and executive brain function in patients when they are initially diagnosed with ADHD," says Adler.
  • Researchers then carefully tracked their psychiatric health on a weekly basis through standardized tests for signs and symptoms of sluggish cognitive tempo, ADHD, as well as other measures of brain function.

New Study Finds ADHD Test Serves as a Better Indicator of Medication Effects

Retrieved on: 
Tuesday, June 8, 2021
Mental health, Health, Science, Pharmaceutical, Research, Attention deficit hyperactivity disorder, Psychiatry, Childhood psychiatric disorders, Psychology, Amphetamine, Abnormal psychology, Methylphenidate, Psychiatric diagnosis, Attention deficit hyperactivity disorder controversies, Attention deficit hyperactivity disorder management

The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.

Key Points: 
  • The Quantified Behavioral Test (QbTest), serves as a better early indicator of treatment effects for ADHD, confirming that healthcare professionals can confidently use objective data alongside patient feedback regarding treatment effectiveness.
  • View the full release here: https://www.businesswire.com/news/home/20210608005305/en/
    Study finds ADHD test serves as a better early indicator of medication effects than rating scales (Graphic: Business Wire)
    Clinical ADHD treatment procedures typically involve self-rated evaluations of symptoms as a means for measuring medication effects in adults with ADHD.
  • At the first follow up, QbTests activity and inattention measures showed significant effect of medication, compared to ASRS, that indicated only moderate effect.
  • The study proves how important it is to have objective data when managing ADHD symptoms.

ADHD Medications Associated with Reduced Risk of Suicidality in Children with Significant Behavioral Symptoms

Retrieved on: 
Friday, June 4, 2021
Psychiatry, Abnormal psychology, Psychology, Attention deficit hyperactivity disorder, Childhood psychiatric disorders, Amphetamine, Psychiatric diagnosis, Methylphenidate, Externalizing disorders, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

"Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."

Key Points: 
  • "Early diagnosis and treatment of behavioral symptoms with ADHD medication, particularly among children with severe externalizing symptoms, may serve not only to improve learning and behavior problems, but also to decrease suicidality risk."
  • The researchers found that children expressing suicidal tendencies had more externalizing symptoms and were more likely to receive ADHD medication than non-suicidal children.
  • However, among children who demonstrated significant externalizing behaviors, those taking ADHD medications had lesser odds for suicidality, suggesting a moderating role for ADHD medications in these children.
  • They found that children with high externalizing symptoms who were treated with ADHD medications at baseline were less likely to be suicidal one year later.

2021 Worldwide Attention Deficit Hyperactivity Disorder Industry - Understand Targeted Population for Research and Development - ResearchAndMarkets.com

Retrieved on: 
Monday, May 17, 2021
Health, General Health, Psychiatric diagnosis, Psychiatry, Medicine, Articles, Childhood psychiatric disorders, Attention deficit hyperactivity disorder, Amphetamine, Educational psychology, Attention deficit, Disease, Attention deficit hyperactivity disorder controversies, Bipolar disorder

b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nThe research report, Global Attention Deficit Hyperactivity Disorder Epidemiology and Patient Flow Analysis - 2021, provides Attention Deficit Hyperactivity Disorder epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Attention Deficit Hyperactivity Disorder patients, history of the disease at the population level (Attention Deficit Hyperactivity Disorder prevalence, Attention Deficit Hyperactivity Disorder incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nAttention Deficit Hyperactivity Disorder patient flow: Attention Deficit Hyperactivity Disorder prevalence, diagnosed, and drug-treated patients\nDemographics: Attention Deficit Hyperactivity Disorder patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Attention Deficit Hyperactivity Disorder market sizing, assessing market potential, and developing drug forecast models\nIdentify Attention Deficit Hyperactivity Disorder patients segments through age groups, gender, and disease sub-types\nEvaluate Attention Deficit Hyperactivity Disorder market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005615/en/\n'

Supernus Announces FDA Approval of Qelbree™ (SPN-812) for the Treatment of ADHD

Retrieved on: 
Friday, April 2, 2021
Psychoactive drugs, Psychiatry, Amphetamine, Attention deficit hyperactivity disorder, Methylphenidate, Medicine, Childhood psychiatric disorders, Stimulant, Medication, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.

Key Points: 
  • Based on the efficacy demonstrated in the clinical program, we believe Qelbree offers a unique new alternative for the treatment of ADHD, said Jack A. Khattar, President and Chief Executive Officer of Supernus Pharmaceuticals.
  • Qelbree provides prescribing physicians and patients living with ADHD a therapy that is not a controlled substance with proven efficacy and a tolerable safety profile.
  • This approval offers a novel once a day sprinkleable non-stimulant that can be a great option for children and adolescents with ADHD.
  • Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.

Supernus Announces Positive Results from Phase III Study for SPN-812 in Adults with ADHD

Retrieved on: 
Tuesday, December 22, 2020
Health, Clinical research, Design of experiments, Articles, Amphetamine, Methylphenidate, Childhood psychiatric disorders, Clinical trial, Attention deficit hyperactivity disorder, Placebo-controlled study, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

SPN-812 is under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in pediatric patients 6 to 17 years of age.

Key Points: 
  • SPN-812 is under review by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD in pediatric patients 6 to 17 years of age.
  • We now have positive Phase III data proving the efficacy and safety of SPN-812 in a broad range of ADHD patient populations; children 6-11 years old, adolescents 12-17 years old, and adults.
  • The study was a randomized, double-blind, placebo controlled, multicenter, parallel group clinical trial in adult patients diagnosed with ADHD.
  • Patients who completed the study were offered the opportunity to continue into an ongoing open-label safety extension study.

KemPharm Files IND for KP879 for the Treatment of Stimulant Use Disorder

Retrieved on: 
Tuesday, December 22, 2020
Psychoactive drugs, Amphetamine, Phenethylamines, Stimulants, Methylphenidate, Attention deficit hyperactivity disorder, Pemoline, Attention deficit hyperactivity disorder management, Attention deficit hyperactivity disorder controversies

KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).

Key Points: 
  • KemPharm is developing KP879 as an extended-duration, agonist replacement therapy for the treatment of Stimulant Use Disorder (SUD).
  • If the KP879 IND filing is accepted by the FDA, KemPharm intends to initiate efficacy studies of KP879 in 2021.
  • It is anticipated that certain data from previously completed KP415 research may be leveraged for KP879, including pharmacokinetic studies, which KemPharm believes could potentially streamline the development timeline of KP879.
  • KemPharms prodrug product candidate pipeline is focused on the high need areas of attention deficit hyperactivity disorder, or ADHD, and stimulant use disorder.

ADHD: Recognizing the Symptoms - CHADD Aims to Build Understanding During ADHD Awareness Month in October

Retrieved on: 
Tuesday, October 27, 2020
Psychiatry, Attention deficit hyperactivity disorder, Psychology, Mind, Psychiatric diagnosis, Childhood psychiatric disorders, Amphetamine, Psychiatric assessment, Diagnostic and Statistical Manual of Mental Disorders, Attention deficit hyperactivity disorder controversies, Attention deficit hyperactivity disorder predominantly inattentive

But for some, these issues are so pervasive and persistent that they interfere with the activities of daily life.

Key Points: 
  • But for some, these issues are so pervasive and persistent that they interfere with the activities of daily life.
  • How do you know when you or a loved one should seek a professional evaluation?
  • As we mark ADHD Awareness Month in October, CHADD (Children and Adults with Attention-Deficit/Hyperactivity Disorder)the leading nonprofit organization providing support, training, education, and advocacy for the ADHD communityexplains the signs to look for.
  • The classification system found in the Diagnostic and Statistical Manual, Fifth Edition (DSM-5), is the gold standard used by healthcare professionals when evaluating patients for ADHD.